Drug intelligence / Profile preview

hepastem

Development stage: Phase 2
Lead developer: Cellaion
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

HepaStem is an allogeneic cell therapy composed of human heterologous liver progenitor cells (HHALPC), which are derived from healthy donated human livers. Developed by Promethera Biosciences (and subsequently Cellaïon), the therapy is designed to treat severe liver diseases including acute-on-chronic liver failure (ACLF), non-alcoholic steatohepatitis (NASH), and urea cycle disorders (UCD). HepaStem works through a multi-modal mechanism of action, primarily exerting anti-inflammatory and anti-fibrotic effects to reduce liver inflammation and promote tissue regeneration. It is administered via intravenous infusion and has been granted Orphan Drug Designation in the US and Europe for certain indications.

Brand names: HepaStem
Other names: Human Heterologous Liver Progenitor Cells

Beyond the preview

Go deeper on hepastem.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on hepastem.

Explore the full profile